Intrexon Corp. has announced a strategic licensing agreement with Surterra Wellness to utilize Intrexon's Botticelli next generation plant propagation platform for the production of Surterra's specific cannabis cultivars for the Florida market. "The collaboration agreement includes two-stages: 1) an optimization phase in which Intrexon will calibrate its Botticelli™ technology to Surterra's cannabis cultivars; and 2) a production phase in which Surterra will utilize the technology to generate cannabis plantlets for its products, predicted to increase Surterra's production capabilities.", the team with the company explains.
"Applying the Botticelli-platform approach to our current plantlet production will improve our (cultivation) efficiency and consistency and will help ensure superior product integrity and higher yields in our facilities.", says William "Beau" Wrigley, Jr., Chairman and CEO of Surterra Wellness.
"Currently, the most common method of cannabis cultivation is through cloning, which is labor intensive, costly, and challenging due to the risk of disease susceptibility.", the team with the company explains, "Intrexon's Botticelli platform is an advanced tissue culture technology designed to facilitate efficient propagation of plants while maintaining genetic purity and product performance. When compared to conventional cloning processes, Intrexon's Botticelli platform offers the potential to improve scalability and cost efficiency of production, as well as enable consistency of cannabis products."
For more information:
Intrexon
dna.com